Pfizer Inc. PFEannounced that a phase III study evaluating its epilepsy drugLyrica (pregabalin) in pediatric patients met the primary endpoint. The study was evaluating the use of Lyrica Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age, an indication for which Lyrica is not yet approved.
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться